[Value of benzydamine, the first anti-inflammatory vaginal solution].
This clinical study concerns thirty women with vaginal infections caused by Trichomonas and Candida, showing major inflammatory reactions and painful symptomatology: smarting, pruritus, oedema. Its aim is to measure the activity of benzydamine, the first NSAID to appear as a vaginal solution for local application in the treatment of vaginal inflammation and painful symptomatology. The product is prescribed with the etiological treatment. Benzydamine vaginal douche acts most rapidly on local discomfort, the foremost criterion of this study. From the very first application all the patients have noticed substantial relief which can only be attributed to benzydamine and allows for a better observance of the etiological treatment. Owing to its efficacy and immediate action on vaginal inflammation, benzydamine is a real therapeutic contribution to gynecology.
Lévy
G
G
Service de Gynécologie-Obstétrique, CHU de Caen.
D000282:Administration, Intravaginal; D001591:Benzydamine / Q000008:administration & dosage / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use*; D014247:Trichomonas Vaginitis / Q000188:drug therapy*
D011720:Pyrazoles; D001591:Benzydamine
Intérêt de la benzydamine première solution vaginale anti-inflammatoire.